Acute and chronic kidney failure is common in hospitalized patients with COVID-19, yet the mechanism of injury and predisposing factors remain poorly understood. We investigated the role of complement activation by determining the levels of deposited complement components (C1q, C3, FH, C5b-9) and immunoglobulin along with the expression levels of the injury-associated molecules spleen tyrosine kinase (Syk), mucin-1 (MUC1) and calcium/calmodulin-dependent protein kinase IV (CaMK4) in the kidney tissues of people who succumbed to COVID-19. We report increased deposition of C1q, C3, C5b-9, total immunoglobulin, and high expression levels of Syk, MUC1 and CaMK4 in the kidneys of COVID-19 patients. Our study provides strong rationale for the expansion of trials involving the use of inhibitors of these molecules, in particular C1q, C3, Syk, MUC1 and CaMK4 to treat patients with COVID-19.

急性和慢性肾功能衰竭在 COVID-19 住院患者中很常见，但对损伤机制和诱发因素仍知之甚少。我们通过测定沉积补体成分（C1q、C3、FH、C5b-9）和免疫球蛋白的水平以及损伤相关分子脾酪氨酸激酶 (Syk)、粘蛋白-1 的表达水平来研究补体激活的作用。 MUC1) 和钙/钙调蛋白依赖性蛋白激酶 IV (CaMK4) 在死于 COVID-19 的人的肾组织中。我们报告了 COVID-19 患者肾脏中 C1q、C3、C5b-9、总免疫球蛋白的沉积增加以及 Syk、MUC1 和 CaMK4 的高表达水平。我们的研究为扩大涉及使用这些分子抑制剂的试验提供了强有力的理由，特别是 C1q、C3、Syk、